Physician profile
Paul Bates
NPI 1942264726
$5,535.73
in general payments reported to CMS, 2019-2025
26 companies · $935 in 2025
The $935 reported for 2025 was more than what 85% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $535 · 2020: $746 · 2021: $755 · 2022: $714 · 2023: $948 · 2024: $902 · 2025: $935.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,785.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,785.10 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $763.83 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals Lp | $732.22 | 2019-2025 | Farxiga, Breztri |
| Abbvie INC. | $686.04 | 2019-2025 | Vraylar, Synthroid, Ubrelvy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $450.27 | 2019-2025 | Jardiance, Synjardy |
| Kowa Pharmaceuticals America, INC. | $369.98 | 2019-2023 | Livalo, Seglentis |
| Lilly USA, LLC | $363.45 | 2020-2025 | Mounjaro, Zepbound, Jardiance |
| Amarin Pharma, INC. | $350.45 | 2019-2022 | |
| Antares Pharma, INC. | $280.58 | 2021-2025 | Xyosted, Tlando, Nocdurna |
| Glaxosmithkline, LLC. | $247.46 | 2020-2024 | Trelegy Ellipta |
| Currax Pharmaceuticals LLC | $230.17 | 2024-2025 | Contrave |
| Pfizer INC. | $202.45 | 2020-2025 | |
| Amgen INC. | $182.16 | 2019-2025 | Repatha, Otezla, Otezla |
| Merck Sharp & Dohme LLC | $153.09 | 2019-2021 | |
| Exact Sciences Corporation | $105.04 | 2023-2025 | Cologuard Collection Kit |
| Idorsia Pharmaceuticals US INC | $89.53 | 2023-2024 | Quviviq |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $63.61 | 2022-2023 | |
| Allergan, INC. | $51.51 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $49.60 | 2019-2020 | |
| Halozyme INC | $29.33 | 2023 | |
| Biohaven Pharmaceutical Holding Company Ltd. | $22.50 | 2022 | |
| Astellas Pharma US INC | $22.23 | 2023 | Myrbetriq |
| Sanofi Pasteur INC. | $22.22 | 2023 | |
| Esperion Therapeutics, INC. | $18.91 | 2025 | Nexletol |
| Genentech USA, INC. | $18.63 | 2019 | |
| Acella Pharmaceuticals, LLC | $17.44 | 2024 | NP Thyroid 60 |
| Lucid Diagnostics INC. | $13.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Paul Bates listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.